GXI Stock Overview
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Gerresheimer AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €75.60 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.92 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | 0% |
| 5 Year Change | 0% |
| Change since IPO | 40.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| GXI | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0% | -7.8% | -2.2% |
| 1Y | 0% | 26.6% | 6.2% |
Return vs Industry: GXI underperformed the Swiss Life Sciences industry which returned 27.4% over the past year.
Return vs Market: GXI underperformed the Swiss Market which returned 6.1% over the past year.
Price Volatility
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 0% |
| Life Sciences Industry Average Movement | 4.0% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine GXI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1864 | 12,012 | Dietmar Siemssen | www.gerresheimer.com |
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.
Gerresheimer AG Fundamentals Summary
| GXI fundamental statistics | |
|---|---|
| Market cap | CHF 2.32b |
| Earnings (TTM) | CHF 106.88m |
| Revenue (TTM) | CHF 1.88b |
21.7x
P/E Ratio1.2x
P/S RatioIs GXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXI income statement (TTM) | |
|---|---|
| Revenue | €2.01b |
| Cost of Revenue | €1.43b |
| Gross Profit | €585.40m |
| Other Expenses | €471.10m |
| Earnings | €114.30m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 3.31 |
| Gross Margin | 29.09% |
| Net Profit Margin | 5.68% |
| Debt/Equity Ratio | 81.7% |
How did GXI perform over the long term?
See historical performance and comparison